CASE REPORT |
|
Year : 2020 | Volume
: 68
| Issue : 9 | Page : 1988-1990 |
|
Tofacitinib in recalcitrant scleritis: First case report from India
Richa Pyare1, Viswanath Kaushik2, Parthopratim Dutta Majumder1, Jyotirmay Biswas3
1 Department of Uvea, Sankara Nethralaya, Chennai, Tamil Nadu, India 2 Department of Rheumatology, Apollo Hospital, Chennai, Tamil Nadu, India 3 Department of Uvea, Medical and Vision Research Foundations, Sankara Nethralaya, Chennai, Tamil Nadu, India
Correspondence Address:
Dr. Jyotirmay Biswas Department of Uvea Sankara Nethralaya, 18, College Road, Nungambakkam, Chennai - 600 006, Tamil Nadu India
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/ijo.IJO_534_20
|
|
A 65-year-old male presented with redness and pain associated with active necrotizing scleritis in the left eye. He was started on mycophenolate mofetil and oral corticosteroids, to which there was no response detected after 4 weeks. A rheumatology opinion was sought and he was started on tofacitinib, after which there was dramatic clinical improvement. Patients refractory to conventional immunosuppressive therapy can benefit from the new class of immunosuppressive agents, JAK/STAT kinase inhibitors.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|